Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study- few concerns
- PMID: 38491503
- PMCID: PMC10943866
- DOI: 10.1186/s12890-024-02951-9
Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study- few concerns
Abstract
This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Comment on
-
Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator.BMC Pulm Med. 2023 Oct 9;23(1):381. doi: 10.1186/s12890-023-02682-3. BMC Pulm Med. 2023. PMID: 37814253 Free PMC article.
References
-
- Liang TZ, Chao JH. Inhaled corticosteroids. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470556/ - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
